iiinova — where your digital self keeps evolving

HemaSphere Journal @hemasphere-journal.bsky.social · 08/10/2026

Can patient-derived 3D models improve immunotherapy testing in aggressive B-cell lymphoma? In this paper, the authors show that lymphoma spheroids preserve key immune-tumor features & support rapid testing of single agents and combinations. Learn more in the full paper 📰https://hsphere.pub/hrr

000

HemaSphere Journal @hemasphere-journal.bsky.social · 07/10/2026

In this paper, the authors report that ASCT did not improve progression-free or overall survival versus radioimmunotherapy in relapsed or refractory follicular lymphoma and was associated with more secondary malignancies. Delve deeper 🔎https://hsphere.pub/lk0

000

HemaSphere Journal @hemasphere-journal.bsky.social · 06/10/2026

The latest HemaSphere issue spans AI and machine learning, prognostic models, disease biology and emerging therapies across leukemia, lymphoma, myeloma and rare blood disorders. New research for hematology researchers and clinicians. Read it here: hsphere.pub/3a403b

010

HemaSphere Journal @hemasphere-journal.bsky.social · 05/10/2026

This paper identifies ROR1 as a potential target in very high-risk pediatric B-ALL. The authors found high ROR1 expression and susceptibility to ROR1-targeting ADCs in TCF3::HLF leukemia models. Read it here. hsphere.pub/j1q

000

HemaSphere Journal @hemasphere-journal.bsky.social · 02/10/2026

Writing a review is more than collecting papers. It’s about finding a clear story in a fast-moving field and deciding what matters most,. For this review on TP53 mutations in MPNs, collaboration across France and Brazil a brought together different perspectives hsphere.pub/11ca11

000

HemaSphere Journal @hemasphere-journal.bsky.social · 01/10/2026

HemaTopics explore hot topics in hematology. This week, Scientific Editor S. Hibbs discusses how mosquito control, the gut microbiome, and climate change show why ecological thinking matters to hematologic care. Learn more in this paper. 🦋https://hsphere.pub/i52

011

HemaSphere Journal @hemasphere-journal.bsky.social · 30/09/2026

The authors validated the IMS/IMWG genomic staging criteria in 1,209 patients with newly diagnosed multiple myeloma. This paper shows that the criteria identified high-risk disease with poor outcomes despite modern treatment. Learn more about the findings hsphere.pub/9we

001

HemaSphere Journal @hemasphere-journal.bsky.social · 29/09/2026

This paper links BCMA-targeted therapy in multiple myeloma to plasmacytoid dendritic cell depletion and a reduced interferon alpha response, identifying a potential mechanism behind increased viral infection risk. Read it here: hsphere.pub/qlu #MM

000

HemaSphere Journal @hemasphere-journal.bsky.social · 28/09/2026

Inflammation may drive clonal expansion in polycythemia vera. In this paper, the authors explain how ropeginterferon alfa-2b and ruxolitinib may offer complementary effects by targeting distinct aspects of disease biology. Read it here: hsphere.pub/7nw

000

HemaSphere Journal @hemasphere-journal.bsky.social · 23/09/2026

This paper shows that e1a2 BCR::ABL1 CML can follow two clonal pathways. The authors found that a pre-existing mutated clone may persist during treatment, helping explain cytopenias despite falling BCR::ABL1 levels. Discover more: hsphere.pub/wu2

000

HemaSphere Journal @hemasphere-journal.bsky.social · 22/09/2026

In this paper, the authors found no consistent link between temozolomide maintenance and overall survival in primary central nervous system lymphoma after accounting for treatment timing and other factors. 👉 hsphere.pub/97l

010

HemaSphere Journal @hemasphere-journal.bsky.social · 21/09/2026

This paper presents DAISY-MRD, a whole-genome sequencing method that tracks stable passenger variants for MRD detection in pediatric AML. The authors found these markers in all patients studied, supporting broad potential use. hsphere.pub/e2n

000

HemaSphere Journal @hemasphere-journal.bsky.social · 18/09/2026

Don’t ignore the mitochondria. Sci Ed Charles de Bock talked to Dr. Ilaria Pagani about her recent HemaSphere paper that may change how you think about #CML. The message is clear: mitochondrial data may be a biomarker, not background noise. Hear the full conversation: hsphere.pub/sms

000

HemaSphere Journal @hemasphere-journal.bsky.social · 17/09/2026

HemaTopics spotlight developments across hematology. This week, Scientific Editor C de Bock discusses how this paper identifies MEF2C and IL-1β hubs as potential targets in high-risk TCF3::HLF-positive B-ALL. Learn more: hsphere.pub/xd9

000

HemaSphere Journal @hemasphere-journal.bsky.social · 16/09/2026

This paper reports a 91% complete remission rate after one VA-CAG cycle in younger patients with newly diagnosed AML. The authors also found that 84% of patients with a composite complete response achieved MRD-negative remission. Learn more: hsphere.pub/mlw

000

HemaSphere Journal @hemasphere-journal.bsky.social · 10/09/2026

Can a bispecific antibody help extend remission in first-line follicular lymphoma? Three-year EPCORE NHL-2 data suggest that epcoritamab plus bendamustine and rituximab produced high complete response rates, with most patients still in remission at 3 years 🔎https://hsphere.pub/sq0

000

HemaSphere Journal @hemasphere-journal.bsky.social · 09/09/2026

HemaSphere is pleased to announce a new role in our Editorial Team: Patient Editor. We also welcome Mary Shaniqua as our first Patient Editor. Mary will champion the patient voice and commission patient authors to share their perspectives, strengthening patient representation in hematology.

000

HemaSphere Journal @hemasphere-journal.bsky.social · 03/09/2026

Iron deficiency in pregnancy is common, treatable and associated with important maternal and fetal outcomes. This HemaTopics by Sci Ed L Merz uses a personal perspective to highlight barriers to testing and treatment and call for more practical, timely approaches to care 🔥https://hsphere.pub/iv4

000

HemaSphere Journal @hemasphere-journal.bsky.social · 02/09/2026

What happens when patients with #PNH switch between complement inhibitors? Authors report real-world experience from the largest cohort to date, highlighting need to avoid treatment interruption & closely monitor for hemolysis, especially after proximal-to-terminal switches 👉https://hsphere.pub/fn0

000

HemaSphere Journal @hemasphere-journal.bsky.social · 01/09/2026

What's in the August issue of HemaSphere? New research spans lymphoma, #AML, #MDS, multiple myeloma, thrombosis, #SCD and pediatric hematology. Explore the latest issue 🦋https://hsphere.pub/5bp

000

HemaSphere Journal @hemasphere-journal.bsky.social · 31/08/2026

This recent article reviews autoimmune complications associated with peginterferon therapy in polycythemia vera, including type 1 diabetes, thyroid disease and systemic autoimmune disorders. ⤵️ hsphere.pub/sdx

010

HemaSphere Journal @hemasphere-journal.bsky.social · 27/08/2026

What happens when patients with #PNH switch between complement inhibitors? In this paper authors report real-world experience from the largest cohort to date, highlighting the need to avoid treatment interruption 🔷https://hsphere.pub/urp

000

HemaSphere Journal @hemasphere-journal.bsky.social · 26/08/2026

Can flow cytometry help identify #CMML earlier? In this Perspective article, the authors review evidence supporting the use of monocyte immunophenotyping to detect pre-CMML conditions and propose its inclusion in future CMML classification criteria. Read more 📰https://hsphere.pub/qnd

000

HemaSphere Journal @hemasphere-journal.bsky.social · 25/08/2026

Could genetics reveal new ways to improve stem cell mobilization? In this paper, the authors identify 19 signals that regulate circulating CD34+ cells, connecting HSPC trafficking with mobilization and malignant hematopoiesis 🦋https://hsphere.pub/jmb

000

HemaSphere Journal @hemasphere-journal.bsky.social · 24/08/2026

A rare complication can have devastating consequences after CAR T-cell therapy. In this paper, the authors found that IEC-HS was associated with high mortality despite treatment and inflammatory control, highlighting the need for better risk stratification and management. 🦋 hsphere.pub/4g2

010

HemaSphere Journal @hemasphere-journal.bsky.social · 21/08/2026

This is a preview of an upcoming full episode in conversation with Dr. Ilaria Pagani. Does everyone respond to imutinab treatment? Full episode coming soon.

000

HemaSphere Journal @hemasphere-journal.bsky.social · 20/08/2026

Can CAR-T therapy move beyond routine hospitalization? In this paper, the authors describe the first European outpatient cilta-cel program for #MM. Selected patients had high response rates, manageable toxicities, and substantially reduced inpatient bed use 👉 hsphere.pub/45w

000

HemaSphere Journal @hemasphere-journal.bsky.social · 19/08/2026

Finding compatible blood remains a challenge for many patients with sickle cell disease. In this HemaTopics, Sci Ed E Olayemi explores how mistrust, cultural perspectives, and donor policies may limit blood donation among African, Caribbean, and Black communities: hsphere.pub/giw

010

HemaSphere Journal @hemasphere-journal.bsky.social · 18/08/2026

Authors report that high-frequency, low-dose rituximab achieved substantial CLL cell clearance, while acalabrutinib reduced CD20 expression & #CLL cell sensitivity to rituximab. Findings suggest treatment timing may influence the effectiveness of anti-CD20 therapy: hsphere.pub/fvp

000

HemaSphere Journal @hemasphere-journal.bsky.social · 13/08/2026

New evidence-based #EHA guidelines on diagnostics, treatment and follow-up of Hodgkin lymphoma. Read them hsphere.pub/HL_2026

000

HemaSphere Journal @hemasphere-journal.bsky.social · 12/08/2026

In this paper, the authors show that short-course vemurafenib plus cobimetinib achieved high response rates in relapsed or refractory HCL, while adding obinutuzumab produced deeper MRD-negative responses after relapse or nonresponse 📰https://hsphere.pub/hno

000

HemaSphere Journal @hemasphere-journal.bsky.social · 11/08/2026

IGLV3-21R110 may help identify patients with early-stage CLL at higher risk of progression. In this paper, the authors show it predicts shorter event-free survival and reduced ibrutinib effectiveness, supporting its value as a prognostic biomarker. hsphere.pub/z46

000

HemaSphere Journal @hemasphere-journal.bsky.social · 10/08/2026

What happens when a researcher discovers an error after publication? This HemaTopics reflects on identifying a data error, issuing a correction & the value of transparency in research. Honest corrections strengthen trust in science & improve the research record 👉

hsphere.pub

The tale of a transposition error

Click on the article title to read more.

000

HemaSphere Journal @hemasphere-journal.bsky.social · 07/08/2026

Host Dr Charles de Bock delves into ground-breaking preclinical research exploring the potential of tasquinimod to restore blood cell production and modify the bone marrow microenvironment in #MDS with Dr Manja Wobus and Dr Katja Sockel. Listen and learn 🎧 hsphere.pub/wom

000

HemaSphere Journal @hemasphere-journal.bsky.social · 06/08/2026

The July 2026 issue of HemaSphere is now complete and live. Explore the latest research, consensus recommendations, and clinical advances. Read here 👉 onlinelibrary.wiley.com/toc/2572924…

020

HemaSphere Journal @hemasphere-journal.bsky.social · 31/07/2026

In this paper, the authors developed ADLiB, a cfDNA-based liquid biopsy platform that distinguished malignant from benign lymphadenopathy with 95% sensitivity and 92% accuracy. This approach could improve #lymphoma diagnosis in resource-limited settings.. 📰https://bit.ly/4dDkXgr

000

HemaSphere Journal @hemasphere-journal.bsky.social · 30/07/2026

#ND-LCH has few effective treatment options. In this paper, the authors found that #MAPK inhibitors improved clinical outcomes in 55% of children and MRI findings in 74%, with manageable side effects. Discover the findings: bit.ly/4vr1EwA

000

HemaSphere Journal @hemasphere-journal.bsky.social · 29/07/2026

For previously untreated #FL patients ineligible for chemoimmunotherapy, the authors found that adding ibrutinib to rituximab improved progression-free survival and response rates versus rituximab alone. This paper explores the trade-off between efficacy and safety 👉https://hsphere.pub/fgs

000

HemaSphere Journal @hemasphere-journal.bsky.social · 23/07/2026

In relapsed/refractory #AL amyloidosis, teclistamab produced rapid, deep hematologic responses and meaningful organ responses in a heavily pretreated cohort. Infection risk remains a key concern, with findings supporting concomitant immunoglobulin replacement therapy. 📰 hsphere.pub/70f

000

HemaSphere Journal @hemasphere-journal.bsky.social · 21/07/2026

🚨Explore the June issue: new EHA recommendations for hemoglobinopathies, plus advances in PNH, CAR T-cell therapy, FL, liquid biopsy and lymphoma biology across hematology. hsphere.pub/gjk👉 hsphere.pub/gjk #openaccess

010

HemaSphere Journal @hemasphere-journal.bsky.social · 20/07/2026

New EHA Guidelines for #CLL take a more holistic approach to care, from diagnosis and active surveillance through treatment decisions and Richter transformation. Read more:https://bit.ly/4veuXTm

000

HemaSphere Journal @hemasphere-journal.bsky.social · 17/07/2026

Ever wonder why some cancer models don’t quite match real patients? Here's the truth. 🧬Knock-in mouse models show that natural mutation levels matter—and that biallelic TP53 loss is what truly drives leukemia #CancerResearch hsphere.pub/d3z

011

HemaSphere Journal @hemasphere-journal.bsky.social · 16/07/2026

Phase IB/II trial of obinutuzumab, venetoclax and lenalidomide in high tumor burden follicular lymphoma: primary analysis of the LEVERAGE trial. Read more about this 👉https://bit.ly/4uRBYtj account=@chanyooncheah

000

HemaSphere Journal @hemasphere-journal.bsky.social · 13/07/2026

This paper suggests that some patients with relapsed or refractory multiple myeloma can maintain durable remission after stopping bispecific antibody therapy. The authors also report gradual immune recovery and lower infection risk over time. Read more: bit.ly/3PQNcPD #MM

021

HemaSphere Journal @hemasphere-journal.bsky.social · 09/07/2026

This paper highlights #MAPK inhibitors as a promising therapeutic approach for children with neurodegenerative Langerhans cell histiocytosis. The authors report clinical and MRI improvement in many patients, with manageable safety findings. 👉https://hsphere.pub/xga

000

HemaSphere Journal @hemasphere-journal.bsky.social · 08/07/2026

This study reveals active crosstalk between lymphoma cells and M2-like TAMs, as well as TAM-mediated resistance mechanisms to CD19 #CAR T cells, which can be circumvented by targeting FR-beta. 👉https://bit.ly/4dOG3XR

000

HemaSphere Journal @hemasphere-journal.bsky.social · 07/07/2026

000

HemaSphere Journal @hemasphere-journal.bsky.social · 02/07/2026

This paper shows that CDK6 inhibition enhances interferon responsiveness in #MPN cells, identifying a potential therapeutic window for combining palbociclib with pegIFNα, supporting further study of this approach in MPN therapy. Read here 📰https://bit.ly/4uO44p2

000

HemaSphere Journal @hemasphere-journal.bsky.social · 01/07/2026

Var‑cel (ARI-0001) CAR‑T shows strong positive outcomes in R/R Mantle Cell Lymphoma #MCL: 89% ORR, 78% CR, minimal severe CRS/ICANS, and long survival (PFS 15.4/OS 35.2 mo) in a Spanish multicenter cohort. Read the details here: bit.ly/4nGObOR

000

HemaSphere Journal @hemasphere-journal.bsky.social · 30/06/2026

This paper shows that JAK2-V617F mutant #HSCs can outcompete normal HSCs and initiate #MPN without irradiation or elevated cytokines. Delve deeper 🔎https://bit.ly/4tzIiVB

000